Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mil60 vs Bevacizumab in First-line Non-squamous NSCLC
NCT03196986Phase 3Completed
- Sponsor
- Beijing Tianguangshi Pharmaceutical Technology
- Start
- Aug 2017
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of Bevanovis in non-small cell lung cancer (NSCLC), sponsored by Beijing Tianguangshi Pharmaceutical Technology. Started Aug 2017; status: completed.
02
Drugs
Bevanovis
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03196986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03196986.